RecruitingEarly Phase 1NCT05043701

Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma

Individualized Systems Medicine Strategy for Targeting Cancer Stem Cells in Patients With Recurrent Glioblastoma (ISM-GBM)


Sponsor

Oslo University Hospital

Enrollment

15 participants

Start Date

Mar 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

A study to determine the feasibility and safety of individualized cancer stem cell targeted therapy based on high-throughput functional profiling of FDA/EMA-approved drugs in patients with GBM that has recurred or progressed following standards-of-care (RT, TMZ).


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This trial uses lab testing of individual patient tumor cells to help personalize treatment for people with recurrent glioblastoma — a particularly aggressive brain cancer. A small piece of tumor tissue is tested against many drugs to find which ones are most likely to work for that specific patient. **You may be eligible if...** - You are between 18 and 70 years old - Your glioblastoma has come back (been histologically verified) - A biopsy can be performed to obtain enough live tumor cells for lab testing - You are ambulatory and in reasonably good health (ECOG 0–1) - Your bone marrow, liver, and heart function are adequate - You are able to give informed consent **You may NOT be eligible if...** - You are participating in another clinical trial that might interfere with this one - There is another medical reason that in the doctor's view makes participation unsafe or impractical Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPersonalized drug combination

A personalized drug combination will be prescribed to each patient based on the functional drug screen


Locations(1)

Oslo University Hospital

Oslo, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05043701


Related Trials